Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination with Monoclonal Antibodies in Adult Patients with Relapsed and/or Refractory Multiple Myeloma

Protocol No

TAKEDA-TAK-981-1503

Principal Investigator

Meera Mohan

Phase

I/II

Summary

This study is being done to determine the safety and tolerability of TAK-981 in combination with monoclonal antibodies in patients with R/R MM and to determine the recommended Phase 2 dose. Phase 2 is being done to evaluate the efficacy of TAK-981 in combination with monoclonal antibodies in patients with RRMM

Description

A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma.

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL

Sub Category

Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers

ClinicalTrials.gov

go to website